ClinicalTrials.gg
RecruitingNCT05317247CAGE-TBUpdated May 6, 2026

Cough Audio Classification as a TB Triage Test

An observational study in Tuberculosis, sponsored by University of Stellenbosch. Recruiting at 2 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Stellenbosch · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,751
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Tuberculosis with a site in South Africa — 21 open to participants now, 35 under way, 8 of them phase 3. Tuberculosis · South Africa.

Planned enrollment
5th of 34
1,751 · median 770
Started
2022
with 12 others
Observational
34 of 210
3 open now
Primary completion
2026-06
later than 13 of 34 live
Registered
177th of 210
by date
Lead sponsor
8 of 210
University of Stellenbosch

Among the 210 studies in Tuberculosis with a site in South Africa, this one is the 5th largest by planned enrollment of the 34 observational ones that give a count, is one of 13 that started in 2022, is one of 34 observational ones, reaches primary completion later than 13 of the 34 other live ones, and was the 177th registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

21 of the 210 studies in Tuberculosis with a site in South Africa are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Tuberculosis with a site in South Africa, or all of them as a file.
02

Study summary

TB is the single biggest infectious cause of death (1.5 million died in 2018), killing more HIV-positive people than any other disease, and is arguably the most important poverty-related disease in the world. TB's estimated incidence in Africa has been declining over recent years but progress is slow and plateauing. To avert stagnation, truly innovative and ambitious technologies are needed, especially those that improve case finding and time-to-diagnosis as, in mathematical models based on the TB care cascade framework, interventions that accomplish this will have the most impact on disrupting population-level transmission, including when deployed at facilities where patients are readily accessible. Critically, these interventions (triage tests) must promote access to confirmatory testing (e.g., Xpert MTB/RIF Ultra) by enabling patients to be referred rapidly and efficiently during the same visit. The investigators will optimise and evaluate a technology that, aside from the investigators early case-controlled study to show feasibility, is hitherto not meaningfully investigated for TB. This gap is alarming given, on one hand, the enormity of the TB epidemic and the need for a triage test and, on the other hand, promising proofs-of-concept that demonstrate high diagnostic accuracy of cough audio classifier for respiratory diseases such as pneumonia, asthma. pertussis, croup, and COPD. In some cases, these classification systems are CE-marked, awaiting FDA-approval, and subject to late-stage clinical trials. This demonstrates the promise of the underlying technological principle. CAGE-TB's innovation is further enhanced by: applying advanced machine learning methods that the team have specifically developed for TB patient cough audio analysis, use of mixed methods research - drawing from health economics, implementation science, and medical anthropology - to inform product design and assess barriers and facilitators to implementation, and uniquely for a TB diagnostic test, its potential deployment as a pure mHealth (smartphone-based) innovation that mitigates many barriers that typically jeopardise TPP criteria fulfilment.

Read the detailed description

CAGE-TB is a diagnostic evaluation study that assesses a TB cough audio signature's potential to be used in a smartphone application to detect potential TB from a cough sound to screen (triage) TB. The purpose of CAGE-TB is to promote the adoption of mobile health (mHealth) based cough audio triage testing for active pulmonary TB in health facilities located in high burden settings. The study is funded by the EDCTP2 programme supported by the European Union and involves four international partners. The study participants, older than 12 years, include participants who have a cough for a duration exceeding two weeks that present to healthcare clinics where the investigators have clinical recruitment infrastructure and permissions to conduct TB research. In this two-phase observational, cross-sectional study, each participant will be seen once only, at diagnosis, and no intervention is planned. In the first phase, the investigators will collect data from a discovery cohort, which will be used to train a machine learning algorithm. During the second phase, data will be collected from a validation cohort, comprising a larger number of participants from two geographically distinct study sites, which will be used to evaluate the performance of the algorithm. The aims of this study are to: (1) generate and separately validate a cough audio classifier that meets WHO triage test TPP sensitivity and specificity criteria. This aim lays the foundation for CAGE-TB by generating a classifier and a common public resource (cough sounds database) for potential later use in other studies. (2) Produce data on potential cost savings of cough audio app for triage by collecting primary data to demonstrate potential cost savings estimated using state-of-the-art methods to satisfy a key TPP criterion (\<USD 2 per patient). This aim will support the further independent evaluation of the classifier, including in clinical trials focused on patient endpoints. (3) Package the technology into an easy-to-use smartphone app. Many TB tests offer improvements in accuracy and cost, but are not widely adopted. This aim is designed to mitigate this risk with the cough classifier and by using the advantages of mHealth, a product may be delivered that is readily usable by nurses, trusted by patients, and capitalised upon by healthcare providers. Accomplishing this requires incorporating important features into the mobile application, such as connectivity, automated reporting, build-in guidance, and quality control, which are important but often neglected components of the WHO triage test TPP profile. (4) Form a foundation for subsequent studies where the app will be evaluated to measure its impact on patient care, to build evidence for global policy change and adoption. The objectives of CAGE-TB include: (1.1) sampling (cough audio, sputum microbiology) all patients with a prolonged cough entering primary health facilities irrespective of reason for presentation (n=473 in Cape Town discovery cohort); (1.2) use machine learning to develop a cough audio classifier to differentiate between TB and non-TB coughs; (1.3) evaluation of the classifier for sensitivity and specificity in new validation cohorts (n=511 in Cape Town, n=767 in Kampala); (2) in both settings, the investigators will use validated tools to calculate potential provider costs averted and conduct mixed methods research to identify barriers and facilitators to inform development of the mHealth solution (smartphone app) intended for use by minimally trained health workers with the final product ideally functioning offline without necessarily needed to sync to an online server for processing done at Stichting-Amsterdam Institute for Global Health and Development (AIGHD); (3) the app will be further refined and made user-friendly, simple and visually intuitive based on study feedback towards a more final product which is free for any person to use; and (4) this mHealth solution packaged into a smartphone app will be sent for review to large international stakeholders such as the Foundation for Innovation and Diagnostics (FIND) and the World Health Organization (WHO) and lead by colleagues at AIGHD with Stellenbosch University and Makerere University input to make this TB triage application relevant for use in African settings and populations.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Triage
  • Cough audio classification
  • Smartphone application
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a cough of at least two weeks duration self-reporting to primary care clinics in Cape Town and Kampala, in areas with a high prevalence of TB.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participant must be at least 12 years old
  • participant must have a prolonged cough (for at least two weeks)
  • participant must provide
  • participant shall have a known status or be willing to undergo standard of care HIV testing and counseling

Exclusion criteria

Exclusion Criteria:

  • individuals who refuse
  • individuals who have received treatment for TB in the 60 days prior to enrolment
  • individuals who are unable to provide a sputum specimen for microbiological testing
  • individuals who have haemoptysis or a bloody cough with any forced coughs for audio recordings
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,751 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Discovery Cohort

    An anticipated number of 473 participants will be recruited in Cape Town, South Africa. Data (cough audio) will be collected and used to train a machine learning algorithm. The cough audio signal specific for TB will be refined. During the discovery phase, the ground truth obtained through biological testing of sputum specimens will be used to inform the machine learning.

    Diagnostic Test: Cough sounds

  • Validation Cohort

    In the validation phase, the cough audio signature will have its sensitivity and specificity measured in new patients in Cape Town, South Africa (n=511) and Kampala, Uganda (n=767). The data will be used to evaluate the performance of the algorithm.

    Diagnostic Test: Cough sounds

Interventions

  • Diagnostic testCough sounds

    The investigators will discover a cough audio signature and then validate it.

06

What researchers measure

Primary outcomes

  1. Develop and validate algorithms that can distinguish between TB and non-TB coughs

    Cough audio data will be collected and used to define the cough audio signal specific for TB. The optimised TB audio signature will then have its sensitivity and specificity measured in new patients to evaluate the performance of the algorithms.

    Time frame: 24 months

  2. Finalised smartphone-based mHealth application

    The best-performing algorithm will be incorporated into a smartphone app, which will be designed with human-centered approach, that can be used as a point-of-care triage test for TB.

    Time frame: 30 months

  3. Avert unnecessary Ultra tests

    The investigators will calculate potential cost savings that the application will be able to facilitate to avoid unnecessary tests.

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual data will be stored and handled confidentially and anonymously. Research data will be stored under an identification code that relates to individual participants. Only the code number will be used for study documentation, annual progress reports and research publications. To trace data to an individual participant, an identification code list will be made to link the encoded data to the subject. Only the members of the research team, the site-independent monitors, members of the health care inspection, and members of the relevant Medical Ethics Committee can view research data that can be linked to individual participants. Access to the central database will be controlled via a combination of user roles and study configuration. Users are only granted privileges defined for their role in the study. The applicants will need to submit a proposal to the Trial Steering Committee for review, the applicants will also need to sign a DTA with Stellenbosch University.

Supporting information: Study protocol, Informed consent form

Time frame: Data will be shared one year after study completion.

Access criteria: Applicants will need to submit an application to the Trial Steering Committee for data access. The Trial Steering Committee will review the application. The applicant will also need to sign a DTA with Stellenbosch University.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Jun 2026, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Apr 7, 2022
StartActual
Apr 19, 2022
Primary completionEst.
Jun 2026
CompletionEst.
Dec 30, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05317247
Lead sponsor
University of Stellenbosch
Collaborators
Amsterdam Institute for Global Health and Development, University of Göttingen, Makerere University
Responsible party
Grant Theron (Professor, University of Stellenbosch) — Principal investigator
First posted
Apr 7, 2022
Start date
Apr 19, 2022
Primary completion
Jun 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Grant Theron, PhD
Contact
gtheron@sun.ac.za
+27 21 9389693
Daphne Naidoo, Hons
Contact
daphnenaidoo@sun.ac.za
+27 60 5037703
Grant Theron, PhD
principal investigator · University of Stellenbosch

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion